These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34978711)

  • 1. In vitro assays for the functional characterization of (psychedelic) substances at the serotonin receptor 5-HT
    Pottie E; Stove CP
    J Neurochem; 2022 Jul; 162(1):39-59. PubMed ID: 34978711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT
    Pottie E; Dedecker P; Stove CP
    Biochem Pharmacol; 2020 Dec; 182():114251. PubMed ID: 32998000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor.
    Pottie E; Cannaert A; Stove CP
    Arch Toxicol; 2020 Oct; 94(10):3449-3460. PubMed ID: 32627074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT
    de la Fuente Revenga M; Jaster AM; McGinn J; Silva G; Saha S; González-Maeso J
    ACS Chem Neurosci; 2022 Aug; 13(16):2436-2448. PubMed ID: 35900876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT
    Schmitz GP; Jain MK; Slocum ST; Roth BL
    ACS Chem Neurosci; 2022 Aug; 13(16):2386-2398. PubMed ID: 35894503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Setup of a Serotonin 2A Receptor (5-HT2AR) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR Bioassays Are Not Suited for Universal Activity-Based Screening of Biofluids for New Psychoactive Substances.
    Pottie E; Cannaert A; Van Uytfanghe K; Stove CP
    Anal Chem; 2019 Dec; 91(24):15444-15452. PubMed ID: 31725281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT
    Pottie E; Poulie CBM; Simon IA; Harpsøe K; D'Andrea L; Komarov IV; Gloriam DE; Jensen AA; Kristensen JL; Stove CP
    ACS Chem Neurosci; 2023 Aug; 14(15):2727-2742. PubMed ID: 37474114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
    Poulie CBM; Pottie E; Simon IA; Harpsøe K; D'Andrea L; Komarov IV; Gloriam DE; Jensen AA; Stove CP; Kristensen JL
    J Med Chem; 2022 Sep; 65(18):12031-12043. PubMed ID: 36099411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hallucinogens and Serotonin 5-HT
    López-Giménez JF; González-Maeso J
    Curr Top Behav Neurosci; 2018; 36():45-73. PubMed ID: 28677096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Selective" serotonin 5-HT
    Casey AB; Cui M; Booth RG; Canal CE
    Biochem Pharmacol; 2022 Jun; 200():115028. PubMed ID: 35381208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective 5-HT
    Jensen AA; Halberstadt AL; Märcher-Rørsted E; Odland AU; Chatha M; Speth N; Liebscher G; Hansen M; Bräuner-Osborne H; Palner M; Andreasen JT; Kristensen JL
    Biochem Pharmacol; 2020 Jul; 177():113979. PubMed ID: 32298690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin 2A Receptor (5-HT
    Duan W; Cao D; Wang S; Cheng J
    Chem Rev; 2024 Jan; 124(1):124-163. PubMed ID: 38033123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of 5-HT
    Wallach J; Cao AB; Calkins MM; Heim AJ; Lanham JK; Bonniwell EM; Hennessey JJ; Bock HA; Anderson EI; Sherwood AM; Morris H; de Klein R; Klein AK; Cuccurazzu B; Gamrat J; Fannana T; Zauhar R; Halberstadt AL; McCorvy JD
    Nat Commun; 2023 Dec; 14(1):8221. PubMed ID: 38102107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
    Halberstadt AL; Chatha M; Klein AK; McCorvy JD; Meyer MR; Wagmann L; Stratford A; Brandt SD
    Neuropharmacology; 2020 Aug; 172():107856. PubMed ID: 31756337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
    Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Mechanism of the Non-hallucinogenic 5-HT
    Cunningham MJ; Bock HA; Serrano IC; Bechand B; Vidyadhara DJ; Bonniwell EM; Lankri D; Duggan P; Nazarova AL; Cao AB; Calkins MM; Khirsariya P; Hwu C; Katritch V; Chandra SS; McCorvy JD; Sames D
    ACS Chem Neurosci; 2023 Jan; 14(1):119-135. PubMed ID: 36521179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
    Rickli A; Moning OD; Hoener MC; Liechti ME
    Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal models of serotonergic psychedelics.
    Hanks JB; González-Maeso J
    ACS Chem Neurosci; 2013 Jan; 4(1):33-42. PubMed ID: 23336043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a hallucinogenic serotonin 5-HT
    Zhang G; Cinalli D; Stackman RW
    Hippocampus; 2017 May; 27(5):558-569. PubMed ID: 28176400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors.
    Vargas MV; Dunlap LE; Dong C; Carter SJ; Tombari RJ; Jami SA; Cameron LP; Patel SD; Hennessey JJ; Saeger HN; McCorvy JD; Gray JA; Tian L; Olson DE
    Science; 2023 Feb; 379(6633):700-706. PubMed ID: 36795823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.